Lynestrenol | CAS#52-76-6 | synthetic hormone

MedKoo Cat#: 584567 | Name: Lynestrenol

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lynestrenol is a synthetic progestational hormone used often in mixtures with estrogens as an oral contraceptive.

Chemical Structure

Lynestrenol

CAS#52-76-6

Theoretical Analysis

MedKoo Cat#: 584567

Name: Lynestrenol

CAS#: 52-76-6

Chemical Formula: C20H28O

Exact Mass: 284.2140

Molecular Weight: 284.44

Elemental Analysis: C, 84.45; H, 9.92; O, 5.62

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350.00	2 Weeks
1g	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Lynestrenol; HSDB 7899; IND 1006

IUPAC/Chemical Name

19 Norpregn-4-en-20-yn-17-ol, (17alpha)-

InChi Key

YNVGQYHLRCDXFQ-JBKQDOAHSA-N

InChi Code

InChI=1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20+/m0/s1

SMILES Code

C#C[C@@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CCCC[C@]4([H])[C@@]3([H])CC[C@]12C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Lynestrenol (Ethinylestrenol) is a synthetic progestational hormone, an agonist of the progesterone receptor and has weak androgenic and estrogenic activity.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	56.0	196.88

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 284.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Uzan S, Denis C, Pomi V, Varin C. Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast disease. Eur J Obstet Gynecol Reprod Biol. 1992 Feb 28;43(3):219-27. PubMed PMID: 1563574. 2: Verspyck E, Marpeau L, Lucas C. Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial. Eur J Obstet Gynecol Reprod Biol. 2000 Mar;89(1):7-13. PubMed PMID: 10733017. 3: Huovinen KJ, Lähteenmäki P, Kärkkäinen J, Tikkanen MJ. Lynestrenol induced therapeutic amenorrhea: effects of dose reduction on serum sex-hormones and lipids. Acta Obstet Gynecol Scand. 1992 Apr;71(3):175-80. PubMed PMID: 1317638. 4: Huovinen K, Tikkanen MJ, Varonen S, Wilska ML, Westermarck T, Vesterinen H. The effect of peroral lynestrenol on serum lipids and lipoproteins in therapeutic amenorrhea of mentally retarded women. Acta Obstet Gynecol Scand. 1990;69(1):35-40. PubMed PMID: 2346078. 5: Pyörälä T, Vähäpassi J, Huhtala M. The effect of lynestrenol and norethindrone on the carbohydrate and lipid metabolism in subjects with gestational diabetes. Ann Chir Gynaecol. 1979;68(2):69-74. PubMed PMID: 507743. 6: Huovinen K, Tikkanen MJ, Autio S, Härkönen T, Lommi L, Varonen S, Wilska ML. Serum lipids and lipoproteins during therapeutic amenorrhea induced by lynestrenol and depot-medroxyprogesterone acetate. Acta Obstet Gynecol Scand. 1991;70(4-5):349-54. PubMed PMID: 1836088. 7: Korhonen T, Turpeinen M, Tolonen A, Laine K, Pelkonen O. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66. doi: 10.1016/j.jsbmb.2007.09.025. Epub 2008 Feb 15. PubMed PMID: 18356043. 8: Coert A, Geelen J, van der Vies J. Metabolites of lynestrenol acetate in the bile of rats after intravenous administration; a comparison with lynestrenol. Acta Endocrinol (Copenh). 1975 Apr;78(4):791-800. PubMed PMID: 1173966. 9: Falcão A, Vaz-da-Silva M, Gama H, Nunes T, Almeida L, Soares-da-Silva P. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. Epilepsy Res. 2013 Aug;105(3):368-76. doi: 10.1016/j.eplepsyres.2013.02.020. Epub 2013 Apr 6. PubMed PMID: 23570863. 10: Regidor PA, Regidor M, Schmidt M, Ruwe B, Lübben G, Förtig P, Kienle E, Schindler AE. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol. 2001 Jun;15(3):202-9. PubMed PMID: 11447732. 11: Odlind V, Weiner E, Victor A, Johansson ED. Effects on sex hormone binding globulin of different oral contraceptives containing norethisterone and lynestrenol. Br J Obstet Gynaecol. 1980 May;87(5):416-21. PubMed PMID: 6155933. 12: Bloch B. Lynestrenol as a contraceptive preparation. Experience with a micro-dosage formulation. S Afr Med J. 1975 Apr 12;49(16):657-61. PubMed PMID: 1135704. 13: Yasuda J, Fujii M, Tsukamoto K, Yamamoto T, Honjo H, Okada H. [Pharmacokinetics of norethindrone and lynestrenol studied by HPLC (author's transl)]. Nihon Naibunpi Gakkai Zasshi. 1981 Aug 20;57(8):1159-66. Japanese. PubMed PMID: 7319102. 14: Sannes E, Nafstad I. Tissue distribution of 14C-lynestrenol in pregnant rats. Acta Pharmacol Toxicol (Copenh). 1980 Jan;46(1):47-50. PubMed PMID: 7361560. 15: Lindberg M, Foldemo A, Josefsson A, Wiréhn AB. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses. Eur J Contracept Reprod Health Care. 2012 Apr;17(2):106-18. doi: 10.3109/13625187.2012.658925. Epub 2012 Mar 4. PubMed PMID: 22385398. 16: Richter K. )Significance of lynestrenol (Orgametril)-induced amenorrhea in the therapy of endometriosis externa. Wien Klin Wochenschr. 1968 May 31;80(22):432-5. German. PubMed PMID: 5701105. 17: Hem AL, Sannes E, Nafstad I, Nicolaissen B. Effects of oral lynestrenol administration on prenatal and postnatal progeny development in rabbits. NIPH Ann. 1984 Dec;7(2):41-5. PubMed PMID: 6531137. 18: Lejeune B, Wilkin P. [Histological changes observed in the treatment of endometrial glandular epithelioma with lynestrenol]. J Gynecol Obstet Biol Reprod (Paris). 1977 Dec;6(8):1159-69. French. PubMed PMID: 608932. 19: Sannes E, Lyngset A, Nafstad I. Teratogenicity and embryotoxicity of orally administered lynestrenol in rabbits. Arch Toxicol. 1983 Jan;52(1):23-33. PubMed PMID: 6838375. 20: Siddique YH, Afzal M. In vivo induction of sister chromatid exchanges (SCEs) and chromosomal aberrations (CAs) by lynestrenol. Indian J Exp Biol. 2005 Mar;43(3):291-3. PubMed PMID: 15816420.